Lipid Peroxidation and Oxidative imbalance: Early functional events in Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 6, Issue 2, 2004, Pages 171-175

  Praticò, Domenico ^a   Sung, Syun ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alzheimer's disease; Frontotemporal dementia; Isoprostanes; Mild cognitive impairment; Oxidative stress

Indexed keywords

ALPHA CAROTENE; ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; ISOPROSTANE; LYCOPENE; PROSTAGLANDIN F2; PROSTAGLANDIN F2 ALPHA; REACTIVE OXYGEN METABOLITE; RETINOL; URIC ACID;

ALZHEIMER DISEASE; AUTOPSY; COGNITIVE DEFECT; DEGENERATIVE DISEASE; HUMAN; LIPID PEROXIDATION; MOLECULAR EVOLUTION; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW;

EID: 2342420034     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2004-6209     Document Type: Review

References (32)

1. C.M. Clark, Clinical manifestations and diagnostic evaluation of patients with Alzheimer's disease, in: Neurodegenerative dementias: clinical features and pathological mechanisms, C.M. Clark and J.Q. Trojanowski, eds, New York: McGraw-Hill, 2000, pp. 95-114.
2. Y. Zabar and C.H. Kawas, Epidemiology and clinical genetics of Alzheimer's disease, in: Neurodegenerative dementias: clinical features and pathological mechanisms, C.M. Clark and J.Q. Trojanowski, eds, New York: McGraw-Hill, 2000, pp. 79-94.
3. W.R. Markesbery, Oxidative stress hypothesis in Alzheimer's disease, Free Rad. Biol. Med. 23 (1997), 134-147.
4. D. Praticò and N. Delanty, Oxidative injury in Diseases of the Central Nervous System: Focus on Alzheimer's disease, Am. J. Med. 109 (2000), 577-585.
5. R.A. Floy, Antioxidants, oxidative stress, and degenerative neurological disorders, Proc. Soc. Exper. Biol. Med. 222 (1999), 236-245.
6. M.A. Smith, C.A. Rottkamp, A. Numomura, A.K. Raina and G. Perry, Oxidative stress in Alzheimer's disease, Biochim. Biophys. Acta 1502 (2002), 139-144.
7. D. Praticò, Alzheimer's disease and oxygen radicals: new insights, Biochem. Pharmacol. 63 (2002), 563-567.
8. B. Halliwell and J.M.C. Gutteridge, Free Radicals in Biology and Medicine, 3rd edition Oxford: Oxford University Press. 1999.
9. D. Praticò, In vivo measurement of the redox state, Lipids 36 (2001), 45-47.
10. J.D. Morrow, K.E. Hill, R.F. Burk, T.M. Nammour, K.F. Badr and L.J. Roberts, A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism, Proc. Natl. Acad. Sc. USA 87 (1990), 9383-9387.
11. 2-isoprostanes) are formed in situ in phospholipids, Proc. Natl. Acad. Sci. USA 89 (1992), 10721-10725.
12. D. Praticò, F2-isoprostanes: sensitive and specific noninvasive indices of lipid peroxidation in vivo, Atherosclerosis 147 (1999), 1-10.
13. L.J. Roberts and J.D. Morrow, The generation and actions of isoprostanes, Biochim. Biophys. Acta 1345 (1997), 121-135.
14. 2-isoprostanes in biology and medicine, Trends Endocr. Metabol. 12 (2001), 243-247.
15. 2α, J. Biol. Chem. 270 (1995), 9800-9808.
16. 2α-I: A novel index of lipid peroxidation in humans, Proc. Natl. Acad. Sci. USA 95 (1998), 3449-3454.
17. 2α-VI, in human urine, J. Biol. Chem. 273 (1998), 29295-29301.
18. 2-isoprostanes in Alzheimer's disease: evidence of enhanced lipid peroxidation in vivo, FASEB J 12 (1998), 177-178.
19. 2-isoprostanes levels are increased in Alzheimer' disease, Ann Neurol 44 (1998), 410-413.
20. 2α-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity, Ann. Neurol. 48 (2000), 809-812.
21. N. Andreasen, L. Minthon, P. Davidsson, E. Vanmechelen, H. Vanderstichele, B. Winblad and K. Blennow, Evaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer's disease, Arch. Neurol. 58 (2001), 373-379.
22. H. Arai, C.M. Clark, D.C. Ewbank, S. Takase, S. Higuchi, M. Miura, H. Seki, M. Higuchi, T. Matsui, V.M.Y. Lee, J.Q. Trojanowski and H. Sasaki, Cerebrospinal fluid tau as a potential diagnostic marker in Alzheimer's disease, Nurobiol. Aging 19 (1998), 125-126.
23. E.E. Tuppo, L.J. Forman, B.W. Spur, R.E. Chan-Ting, A. Chopra and T.A. Cavalieri, Sign of lipid peroxidation as measured in the urine of patients with probable Alzheimer's disease, Brain Res. Bull. 54 (2001), 565-568.
24. 2-isoprostane levels are incraesed in Alzheimer's disease: evidence of increased oxidative stress in vivo, Alzheim. Reports 2 (1999), 277-282.
25. 2-isoprostanes ands F4-neuroprostanes are not increased in Alzheimer's disease, Ann. Neurol. 52 (2002), 175-179.
26. J.T. Coyle, M.L. Oster-Granite and J.D. Gearhart, The neurobiologic consequences of Down syndrome, Brain Res. Bull. 16 (1986), 773-787.
27. 2α-VI levels: evidence for enhanced lipid peroxidation in vivo, Ann. Neurol. 48 (2000), 795-798.
28. C. Flicker, S.H. Ferris and B. Reisberg, Mild cognitive impairment in the elderly: predictors of dementia, Neurology 41 (1991), 1006-1009.
29. R.C. Petersen, J.C. Stevens, M. Ganguli, E.G. Tangalos, J.L. Cummings and S.T. Dekosky, Practice parameters: early detection of dementia in mild cognitive impairment (an evidence-based review), Neurology 56 (2001), 1133-1142.
30. D. Praticò, C.M. Clark, F. Liun, J. Rokach, V.M.Y. Lee and J.Q. Trojanowski, Increase of oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer's disease, Arch. Neurol. 59 (2002), 972-976.
31. G.M. McKhann, M. Grossman, M.S. Albert and J.Q. Trojanowski, Clinical and pathological diagnosis of frontotemporal dementia: report of work group on frontotemporal dementia and Pick's disease, Ann. Neurol. 58 (2001), 1803-1809.
32. 2α-VI differentiate AD from frontotemporal dementia, Neurology 61 (2003), 475-478.